
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/536881/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment of inherited thrombocytopenias. Haematologica, 2022, 107, 1278-1292.	3.5	6
2	Inherited thrombocytopenias: an updated guide for clinicians. Blood Reviews, 2021, 48, 100784.	5.7	37
3	Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients. ELife, 2021, 10, .	6.0	10
4	Spontaneous splenic rupture due to extramedullary haematopoiesis in a patient with inherited thrombocytopenia. Blood Transfusion, 2021, 19, 257-260.	0.4	1
5	Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial. Haematologica, 2020, 105, 820-828.	3.5	51
6	Eltrombopag in preparation for surgery in patients with severe <i>MYH9</i> â€related thrombocytopenia. American Journal of Hematology, 2019, 94, E199-E201.	4.1	20
7	Loss-of-function mutations in PTPRJ cause a new form of inherited thrombocytopenia. Blood, 2019, 133, 1346-1357.	1.4	40
8	Clinic, pathogenic mechanisms and drug testing of two inherited thrombocytopenias, ANKRD26-related Thrombocytopenia and MYH9-related diseases. European Journal of Medical Genetics, 2018, 61, 715-722.	1.3	27
9	Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable withÂromiplostim. EMBO Molecular Medicine, 2018, 10, 63-75.	6.9	47
10	Prevalence of anemia in hospitalized internal medicine patients: Correlations with comorbidities and length of hospital stay. European Journal of Internal Medicine, 2018, 51, 11-17.	2.2	33
11	Inherited thrombocytopenias—recent advances in clinical and molecular aspects. Platelets, 2017, 28, 3-13.	2.3	51
12	Research at the heart of hematology: thrombocytopenias and platelet function disorders. Haematologica, 2017, 102, 203-205.	3.5	2
13	Inherited Thrombocytopenias. , 2017, , 727-747.		0
14	Revealing eltrombopags promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation. Haematologica, 2016, 101, 1479-1488.	3.5	70
15	Innovation in the field of thrombocytopenias: achievements since the beginning of the century and promises for the future. Haematologica, 2016, 101, 2-4.	3.5	14
16	Clinical and pathogenic features of <i>ETV6</i> -related thrombocytopenia with predisposition to acute lymphoblastic leukemia. Haematologica, 2016, 101, 1333-1342.	3.5	92
17	New roles for mean platelet volume measurement in the clinical practice?. Platelets, 2016, 27, 607-612.	2.3	164
18	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67

CARLO L BALDUINI

#	Article	IF	CITATIONS
19	ACTN1-related thrombocytopenia: identification of novel families for phenotypic characterization. Blood, 2015, 125, 869-872.	1.4	57
20	Inherited thrombocytopenias in the era of personalized medicine. Haematologica, 2015, 100, 145-148.	3.5	9
21	Megakaryocytic emperipolesis and platelet function abnormalities in five patients with gray platelet syndrome. Platelets, 2015, 26, 751-757.	2.3	28
22	Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. Lancet Haematology,the, 2015, 2, e465-e473.	4.6	57
23	Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nature Genetics, 2015, 47, 535-538.	21.4	274
24	Personalized reference intervals for platelet count reduce the number of subjects with unexplained thrombocytopenia. Haematologica, 2015, 100, e338-e340.	3.5	19
25	Lessons in platelet production from inherited thrombocytopenias. British Journal of Haematology, 2014, 165, 179-192.	2.5	35
26	<i>MYH9</i> -Related Disease: A Novel Prognostic Model to Predict the Clinical Evolution of the Disease Based on Genotype-Phenotype Correlations. Human Mutation, 2014, 35, 236-247.	2.5	154
27	Spectrum of the Mutations in Bernard-Soulier Syndrome. Human Mutation, 2014, 35, 1033-1045.	2.5	124
28	Cutaneous involvement by postâ€polycythemia vera myelofibrosis. American Journal of Hematology, 2014, 89, 448-448.	4.1	6
29	Platelet count and aging. Haematologica, 2014, 99, 953-955.	3.5	86
30	Desmopressin and super platelets. Blood, 2014, 123, 1779-1780.	1.4	6
31	Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. Blood, 2014, 124, e4-e10.	1.4	112
32	Small red blood cells mimicking platelets. Blood, 2014, 123, 4014-4014.	1.4	3
33	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. Haematologica, 2014, 99, 1387-1394.	3.5	63
34	MYH9-related disease: Five novel mutations expanding the spectrum of causative mutations and confirming genotype/phenotype correlations. European Journal of Medical Genetics, 2013, 56, 7-12.	1.3	26
35	Inherited thrombocytopenias frequently diagnosed in adults. Journal of Thrombosis and Haemostasis, 2013, 11, 1006-1019.	3.8	87
36	Diagnosis and Management of Inherited Thrombocytopenias. Seminars in Thrombosis and Hemostasis, 2013, 39, 161-171.	2.7	55

#	Article	IF	CITATIONS
37	Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study. British Journal of Haematology, 2013, 162, 112-119.	2.5	86
38	Mean platelet volume for distinguishing between inherited thrombocytopenias and immune thrombocytopenia – response to <scp>B</scp> eyan. British Journal of Haematology, 2013, 163, 413-414.	2.5	7
39	Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and Â-granule deficiency. Haematologica, 2013, 98, 868-874.	3.5	49
40	ANKRD26-related thrombocytopenia and myeloid malignancies. Blood, 2013, 122, 1987-1989.	1.4	145
41	Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombocytopenia. Thrombosis and Haemostasis, 2013, 109, 263-271.	3.4	49
42	High Doses of Romiplostim Induce Proliferation and Reduce Proplatelet Formation by Human Megakaryocytes. PLoS ONE, 2013, 8, e54723.	2.5	36
43	Age- And Sex-Related Variations in Platelet Count in Italy: A Proposal of Reference Ranges Based on 40987 Subjects' Data. PLoS ONE, 2013, 8, e54289.	2.5	190
44	The Case Proteinuria and low platelet count. Kidney International, 2012, 81, 927-928.	5.2	0
45	Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of CPIb (Bolzano mutation). Haematologica, 2012, 97, 82-88.	3.5	99
46	International collaboration as a tool for diagnosis of patients with inherited thrombocytopenia in the setting of a developing country. Journal of Thrombosis and Haemostasis, 2012, 10, 1653-1661.	3.8	22
47	Clonal chromosome anomalies affecting <i><scp>FLI</scp>1</i> mimic inherited thrombocytopenia of the Parisâ€Trousseau type. European Journal of Haematology, 2012, 89, 345-349.	2.2	6
48	Genetics of familial forms of thrombocytopenia. Human Genetics, 2012, 131, 1821-1832.	3.8	85
49	A population-based study of an Italian genetic isolate reveals that mean platelet volume is not a risk factor for thrombosis. Thrombosis Research, 2012, 129, e8-e13.	1.7	17
50	Alteration of Liver Enzymes Is a Feature of the Myh9-Related Disease Syndrome. PLoS ONE, 2012, 7, e35986.	2.5	38
51	Inherited thrombocytopenias. Hamostaseologie, 2012, 32, 259-270.	1.9	53
52	Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation. Thrombosis and Haemostasis, 2012, 107, 1188-1189.	3.4	38
53	Influence of age, sex and ethnicity on platelet count in five Italian geographic isolates: mild thrombocytopenia may be physiological. British Journal of Haematology, 2012, 157, 384-387.	2.5	33
54	Investigational drugs in thrombotic thrombocytopenic purpura. Expert Opinion on Investigational Drugs, 2011, 20, 1087-1098.	4.1	9

#	Article	IF	CITATIONS
55	Megakaryocytes derived from patients with the classical form of Bernard-Soulier syndrome show no ability to extend proplatelets in vitro. Platelets, 2011, 22, 308-311.	2.3	31
56	The irreversibility of platelet aggregation is regulated by myosin IIA, but is not compromised in MYH9-related disease. Thrombosis Research, 2011, 127, 171-173.	1.7	2
57	Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells. Thrombosis and Haemostasis, 2011, 106, 693-704.	3.4	24
58	Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood, 2011, 117, 6673-6680.	1.4	263
59	Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations. Haematologica, 2011, 96, 417-423.	3.5	90
60	Recent advances in the understanding and management of <i>MYH9</i> â€related inherited thrombocytopenias. British Journal of Haematology, 2011, 154, 161-174.	2.5	196
61	Mutations in the 5′ UTR of ANKRD26, the Ankirin Repeat Domain 26 Gene, Cause an Autosomal-Dominant Form of Inherited Thrombocytopenia, THC2. American Journal of Human Genetics, 2011, 88, 115-120.	6.2	200
62	Analysis of 12,517 inhabitants of a Sardinian geographic isolate reveals that predispositions to thrombocytopenia and thrombocytosis are inherited traits. Haematologica, 2011, 96, 96-101.	3.5	70
63	Heavy chain myosin 9-related disease (MYH9-RD): Neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thrombosis and Haemostasis, 2010, 103, 826-832.	3.4	81
64	Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood, 2010, 116, 5832-5837.	1.4	141
65	High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombotic thrombocytopenic purpura: a randomized study. Annals of Hematology, 2010, 89, 591-596.	1.8	115
66	<i>MYH9</i> related disease: four novel mutations of the tail domain of myosinâ€9 correlating with a mild clinical phenotype. European Journal of Haematology, 2010, 84, 291-297.	2.2	32
67	A G to C transversion at the last nucleotide of exon 25 of the MYH9 gene results in a missense mutation rather than in a splicing defect. European Journal of Medical Genetics, 2010, 53, 256-260.	1.3	9
68	Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. Thrombosis and Haemostasis, 2009, 102, 90-96.	3.4	76
69	Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. Journal of Thrombosis and Haemostasis, 2009, 7, 2131-2136.	3.8	86
70	Identification of the first duplication in MYH9-related disease: A hot spot for unequal crossing-over within exon 24 of the MYH9 gene. European Journal of Medical Genetics, 2009, 52, 191-194.	1.3	16
71	Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2009, 124, e13-e18.	1.7	64
72	In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: Are they laboratory artefacts?. Platelets, 2009, 20, 131-134.	2.3	11

#	Article	IF	CITATIONS
73	Absence of CYCS mutations in a large Italian cohort of patients with inherited thrombocytopenias of unknown origin. Platelets, 2009, 20, 72-73.	2.3	4
74	Proplatelet formation in heterozygous Bernard‧oulier syndrome type Bolzano. Journal of Thrombosis and Haemostasis, 2009, 7, 478-484.	3.8	73
75	Dominant inheritance of a novel integrin Â3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica, 2009, 94, 663-669.	3.5	64
76	Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Human Mutation, 2008, 29, 409-417.	2.5	172
77	Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes. Journal of Thrombosis and Haemostasis, 2008, 6, 1900-1907.	3.8	120
78	Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). Nephrology Dialysis Transplantation, 2008, 23, 2690-2692.	0.7	68
79	Clonal chromosome anomalies and propensity to myeloid malignancies in congenital amegakaryocytic thrombocytopenia (OMIM 604498). Haematologica, 2008, 93, 1271-1273.	3.5	34
80	Transfection of the mutant MYH9 cDNA reproduces the most typical cellular phenotype of MYH9-related disease in different cell lines. PathoGenetics, 2008, 1, 5.	5.7	5
81	Heterozygous Ala156Val Mutation in the GPIb Alpha (Heterozygous Bernard-Soulier Syndrome Type) Tj ETQq1 1233-1233.	1 0.784314 1.4	4 rgBT /Overlo 0
82	Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. Platelets, 2007, 18, 579-582.	2.3	53
83	Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica, 2007, 92, 1186-1193.	3.5	53
84	Why the disorder induced by GATA1 Arg216Gln mutation should be called "X-linked thrombocytopenia with thalassemia―rather than "X-linked gray platelet syndrome― Blood, 2007, 110, 2770-2771.	1.4	13
85	Diagnosis of immune thrombocytopenic purpura in children. Current Opinion in Hematology, 2007, 14, 520-525.	2.5	26
86	von Willebrand disease type 2B must be always considered in the differential diagnosis of genetic thrombocytopenias with giant platelets. Platelets, 2006, 17, 149-152.	2.3	20
87	Unexplained recurrent venous thrombosis in a patient withMYH9-related disease. Platelets, 2006, 17, 274-275.	2.3	17
88	Autosomal dominant thrombocytopenias with reduced expression of glycoprotein Ia. Thrombosis and Haemostasis, 2006, 95, 483-489.	3.4	26
89	Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: Relevance for MYH9-related disease. International Journal of Molecular Medicine, 2006, 17, 729.	4.0	9
90	Cord blood in vitro expanded CD41+ cells: identification of novel components of megakaryocytopoiesis. Journal of Thrombosis and Haemostasis, 2006, 4, 848-860.	3.8	23

CARLO L BALDUINI

#	Article	IF	CITATIONS
91	Studies with the Nanobody That Detects the Gain-of-Function of von Willebrand Factor in a Cohort of Patients with Type 2B von Willebrand Disease: Correlation with Platelet Count, VWF Multimers and Molecular Defects Blood, 2006, 108, 1011-1011.	1.4	2
92	Thrombopoietin (TPO) Levels in Inflammatory Disorders with or without Reactive Thrombocytosis Blood, 2006, 108, 1111-1111.	1.4	1
93	Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease. International Journal of Molecular Medicine, 2006, 17, 729-36.	4.0	26
94	Altered cytoskeleton organization in platelets from patients with MYH9-related disease. Journal of Thrombosis and Haemostasis, 2005, 3, 1026-1035.	3.8	50
95	Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations. Human Molecular Genetics, 2005, 14, 3169-3178.	2.9	52
96	Dissecting clinical findings: platelet defects segregate independently of deafness and cataract in a family affected by an apparent syndromic form of macrothrombocytopenia. International Journal of Molecular Medicine, 2005, 16, 437.	4.0	0
97	Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis. Thrombosis and Haemostasis, 2004, 91, 129-140.	3.4	105
98	Inherited Thrombocytopenias: Molecular Mechanisms. Seminars in Thrombosis and Hemostasis, 2004, 30, 513-523.	2.7	34
99	Correlation between the clinical phenotype of MYH9 -related disease and tissue distribution of class II nonmuscle myosin heavy chains. Genomics, 2004, 83, 1125-1133.	2.9	69
100	Expression, activation, and subcellular localization of the Rap1 GTPase in cord blood-derived human megakaryocytes. Experimental Cell Research, 2004, 300, 84-93.	2.6	21
101	Role of splenectomy in inherited thrombocytopenias. Blood, 2004, 104, 1227-1227.	1.4	4
102	Application of a diagnostic algorithm for inherited thrombocytopenias to 46 consecutive patients. Haematologica, 2004, 89, 1219-25.	3.5	51
103	Giant platelet syndromes and the MYH9 mutations. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2004, 10, 187-8.	1.2	6
104	Genetics, clinical and pathological features of glomerulonephrites associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). American Journal of Kidney Diseases, 2003, 41, 95-104.	1.9	94
105	Title is missing!. Medicine (United States), 2003, 82, 203-215.	1.0	30
106	MYH9-Related Disease. Medicine (United States), 2003, 82, 203-215.	1.0	255
107	Hematopoietic Stem-Cell Transplantation for the Bernard–Soulier Syndrome. Annals of Internal Medicine, 2003, 138, 79.	3.9	33
108	Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica, 2003, 88, 582-92.	3.5	91

#	Article	IF	CITATIONS
109	Reversal of Thrombin-Induced Deactivation of CD39/ATPDase in Endothelial Cells by HMG-CoA Reductase Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 894-900.	2.4	44
110	Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chainÂ9 gene. Human Genetics, 2002, 110, 182-186.	3.8	45
111	Immunocytochemistry for the heavy chain of the non-muscle myosin IIA as a diagnostic tool for MYH9-related disorders. British Journal of Haematology, 2002, 117, 164-167.	2.5	47
112	Inherited thrombocytopenias: from genes to therapy. Haematologica, 2002, 87, 860-80.	3.5	92
113	Defective expression of GPIb/IX/V complex in platelets from patients with May-Hegglin anomaly and Sebastian syndrome. Haematologica, 2002, 87, 943-7.	3.5	28
114	Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood, 2001, 97, 1330-1335.	1.4	174
115	A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. British Journal of Haematology, 2001, 113, 1044-1046.	2.5	67
116	Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor. British Journal of Haematology, 2001, 114, 951-953.	2.5	23
117	Factors influencing post-transfusional platelet increment in pediatric patients given hematopoietic stem cell transplantation. Leukemia, 2001, 15, 1885-1891.	7.2	28
118	Transfusion of platelet concentrates cryopreserved with ThromboSol plus low-dose dimethylsulphoxide in patients with severe thrombocytopenia: a pilot study. British Journal of Haematology, 2000, 108, 653-659.	2.5	26
119	Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. Nature Genetics, 2000, 26, 103-105.	21.4	397
120	The Gene for May-Hegglin Anomaly Localizes to a <1-Mb Region on Chromosome 22q12.3-13.1. American Journal of Human Genetics, 2000, 66, 1449-1454.	6.2	40
121	Relationship between size and thiazole orange fluorescence of platelets in patients undergoing highâ€dose chemotherapy. British Journal of Haematology, 1999, 106, 202-207.	2.5	49
122	Incompatibility for CD31 and human platelet antigens and acute graft-versus-host disease after bone marrow transplantation. British Journal of Haematology, 1999, 106, 723-729.	2.5	21
123	A new variant of Bernard-Soulier syndrome characterized by dysfunctional glycoprotein (GP) Ib and severely reduced amounts of GPIX and GPV. British Journal of Haematology, 1998, 103, 1004-1013.	2.5	36
124	Bleeding Tendency of Unknown Origin and Protein Z Levels. Thrombosis Research, 1998, 90, 291-295.	1.7	34
125	Thrombocytopenia, Giant Platelets, and Leukocyte Inclusion Bodies (May-Hegglin Anomaly): Clinical and Laboratory Findings. American Journal of Medicine, 1998, 104, 355-360.	1.5	93
126	Reticulated platelets in primary and reactive thrombocytosis: a reply. British Journal of Haematology, 1998, 101, 389-389.	2.5	0

#	Article	IF	CITATIONS
127	International Prognostic Scoring System and Other Prognostic Systems for Myelodysplastic Syndromes. Blood, 1997, 90, 4232-4235.	1.4	10
128	Thrombopoietin levels in patients with primary and reactive thrombocytosis. British Journal of Haematology, 1997, 99, 281-284.	2.5	131
129	Which tests are most useful to distinguish between clonal and reactive thrombocytosis?. American Journal of Medicine, 1996, 101, 233-235.	1.5	10
130	Ristocetin-induced Platelet Agglutination Stimulates GPIIb/IIIa-dependent Calcium Influx. Thrombosis and Haemostasis, 1995, 73, 689-692.	3.4	14
131	Acquired cyclic thrombocytopeniaâ€ŧhrombocytosis with periodic defect of platelet function. British Journal of Haematology, 1993, 85, 718-722.	2.5	20
132	Effect of different sample preparation methods on the results of the impedance technique in the study of platelet hyper- and hypo-function in whole blood. Thrombosis Research, 1993, 71, 89-94.	1.7	10
133	Heparin Infusion Facilitates ex vivo Spontaneous Platelet Aggregation in Patients with Acute Myocardial Infarction Who Have Undergone Thrombolytic Therapy. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1993, 23, 185-191.	0.3	3
134	An introduction to thrombotic thrombocytopenic purpura. Transfusion Science, 1992, 13, 5-12.	0.6	0
135	Platelet function after in vivo and in vitro treatment with thrombolytic agents. American Journal of Cardiology, 1992, 69, 457-461.	1.6	22
136	Defect of Platelet Aggregation and Adhesion Induced by Autoantibodies Against Platelet Glycoprotein IIIa. Thrombosis and Haemostasis, 1992, 68, 208-213.	3.4	24
137	Platelet Aggregation in Platelet-Rich Plasma and Whole Blood in 120 Patients with Myeloproliferative Disorders. American Journal of Clinical Pathology, 1991, 95, 82-86.	0.7	59
138	An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer, 1991, 68, 2310-2318.	4.1	33
139	Effect of GPIIb-IIIa complex ligands on calciumion movement and cytoskeleton organization in activated platelets. Biochemical and Biophysical Research Communications, 1988, 154, 258-264.	2.1	33
140	Interrelation of platelet aggregation, release reaction and thromboxane A2 production. Biochemical and Biophysical Research Communications, 1988, 156, 822-829.	2.1	14
141	Anomalous Erythrocytes Produced by Rabbits with Liver Damage. Hoppe-Seyler's Zeitschrift Für Physiologische Chemie, 1982, 363, 1341-1346.	1.6	0
142	Behaviour of Young and Old Desialylated Rabbit Erythrocytes in vivo. Hoppe-Seyler's Zeitschrift Für Physiologische Chemie, 1978, 359, 1573-1578.	1.6	16
143	Membrane Sialic Acid and Behaviour in vivo of Rabbit "Stress―Macroreticulocytes. Hoppe-Seyler's Zeitschrift Für Physiologische Chemie, 1977, 358, 1143-1148.	1.6	10
144	<i>In vivo </i> Behaviour of Neuraminidase-Treated Rabbit Erythrocytes and Reticulocytes. Acta Haematologica, 1977, 57, 178-187.	1.4	20